依达拉奉对急性脑梗死患者血清Aβ1—40、Aβ1—42水平的影响

目的探讨依达拉奉治疗对脑梗死患者血清Aβ（1-40）、Aβ（1-42）的影响。方法选择脑梗死患者64例，将其分为依达拉奉组及对照组，每组32例，依达拉奉组给予静脉滴注依达拉奉30mg／日，每日2次，共治疗14天；对照组不使用依达拉奉，其他治疗相同。两组患者分别于治疗前、治疗后3周、治疗后6周抽取静脉血进行Aβ（1-40）、Aβ（1-42）水平检测，将检测结果进行统计学分析。结果治疗前依达拉奉组血清Aβ（1-40）为1．87±0．39．对照组血清Aβ（1—40）为1．83±0．41，两组间无显著差异（P=0．691）。治疗前依达拉奉组血清Aβ（1-42）为1．43±0．26，对照组血清Aβ（1—42）为1．45±0．29（P=0．675），治疗后3、6W，依达拉奉组Aβ（1-40）水平逐步降低（1．79±0．35VS1．34±0．21，P〈0．05）。依达拉奉组Aβ（1—42）于治疗后3W升高（1．61±0．32，P〈0．05）。对照组Aβ（1-40）和Aβ（1—42）水平无显著改变（P〉0．05）。治疗前两组Aβ（1-40）／Aβ（1-42）比率无差异（依达拉奉组1．365，对照组1．314，P=0．582），治疗后3、6W依达拉奉组Aβ（1-40）／Aβ（1-42）比率逐步降低（1．17，0．89），对照组Aβ（1-40）／Aβ（1-42）比率于治疗后3W明显增高（1．58，P=0．048），其后下降，但仍大于治疗前水平。结论依达拉奉可以降低急性脑梗死后血清Aβ（1-40）水平，降低血清Aβ（1—40）／Aβ（1-42）比率。

Effects of edaravone on serum beta-amyloids 1-40 and 1-42 in patients with acute cerebral infarction

Objective To investigate the effects of edaravone on serum Aβ1-40 and Aβ1-42 in patients with acute cerebral infarction. Methods 64 patients with acute cerebral infarction were enrolled within 48 h of onset. Enrolled patients were randomized into edaravone and control groups. Edaravone was infused at a dose of 30 mg, twice daily for 14 days, and control received similar treatment except edaravone infusion. Results There were no significant difference of serum levels of Aβ1-40 and Aβ1-42 before treatment. Three and six weeks after treatment, the serum levels of Aβ1-40 increased gradually in control group. Aβ1-40 level also increased in edaravone group 3 weeks after treatment also, but the level decreased 6 weeks after treatment. The levels of Aβ1-42 in edaravone group were increased at the point of 3 weeks after treatment, and then begin to decline, but at the point of 6 weeks after treatment, which was higher than that of the baseline. The serum levels of beta-amyloids 1-42 in the control group was decreased significantly 3 weeks after treatment and then increased slightly. The ratio of Aβ1-40/ Aβ1-42 decreased gradually 3 weeks after treatment, but it increased significantly at the time of 3W after treatment. Conclusion Edaravone may decrease serum Aβ1-40 and ratio of Aβ1-40/ Aβ1-42 in patients with acute cerebral infarction.